Sandoz joins Biocon to expand the biosimilar market January 22, 2018 Source: WuXi PharmaTech As one of the business units of Novartis, Sandoz is a global leader in biosimilars and has announced a global partnership with Biocon, an Asian biopharmaceutical company, to develop, manufacture and market patients worldwide. Sales of a variety of biosimilars in the field of immunology and oncology. Under the terms of the agreement, the two companies will share responsibility for end-to-end development, manufacturing and global regulatory approval for a range of products, and will distribute costs and distribute profits globally. The responsibility for global commercialization will be divided to take advantage of each company's strengths in a particular region. Sandoz will commercialize leading products in North America and the European Union, and Biocon will lead commercialization in other parts of the world. Sandoz is committed to improving the use of high-quality biosimilars in patients, and currently sells five biosimilars worldwide. In the past, Biocon has successfully developed a range of new biologics, biosimilar antibodies, rh-insulin and insulin analogs. As a pioneer in the field of biosimilars, Biocon successfully launched insulin glargine in Japan, successfully launched trostuzumab and bevacizumab biosimilars in India, and listed in a few emerging markets. Rh-insulin, insulin glargine and the biosimilar drug trastuzumab. Biocon is also the first Indian company to have a biosimilar drug approved by the US FDA. ▲ Mr. Richard Francis, CEO of Sandoz (Source: Sandoz Official Website) Mr. Richard Francis, CEO of Sandoz, said: “Today's cooperation strengthens our position as a leader in biosimilars and enables us to continue to lead in the future. Biocon is a good complement to our biosimilars. This collaboration strengthens our long-term commitment to increase patient access to biological agents." ▲Ms. Carol Lynch, Global Head of Sandoz Biopharmaceuticals (Source: Sandoz Official Website) Ms. Carol Lynch, Global Head of Sandoz Biopharmaceuticals, said: "We will work together to realize the benefits of each value chain from development, manufacturing to commercialization. This collaboration further strengthens our ability to provide patients with next-generation biosimilars." Reference materials: [1] Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars [2] Sandoz official website White Sesame Seeds,Roasted White Sesame Seed,Roasted White Sesame,Big Package White Sesame Seeds Chinese Seasoning (Shandong) Trading Co.,Ltd , https://www.zt-trading.com
Sandoz joins Biocon to expand the biosimilar market